The role of biologics in eosinophilic esophagitis / O papel dos imunobiológicos na esofagite eosinofílica
Desidério, Inara Patrícia; de-Souza, Igor Garcia Sanches; Ferrigolli, Guilherme Gonçalves; Aun, Marcelo Vivolo; Cocco, Renata Rodrigues.
Arq. Asma, Alerg. Imunol
; 5(4): 385-394, out.dez.2021. ilus
Artículo
en Inglés
| LILACS | ID: biblio-1399793
Eosinophilic esophagitis (EoE) is a chronic inflammation in the esophageal mucosa driven by an antigen-mediated abnormal immune response with apparent increasing prevalence worldwide. Genetically predisposed individuals present with a dysfunctional esophageal barrier and an abnormal immune response mediated by Th2 and IgE against certain allergens. Consequently, esophageal lesions can cause dysmotility, fibrosis and loss of esophageal barrier function. Clinical manifestations are age-related and include symptoms of esophageal dysfunction. Diagnosis is established by specific histological features associated with the presence of at least 15 eosinophils per high-power field. Management of EoE includes control of allergic diseases with diet restrictions and/or pharmacological treatment with proton-pump inhibitors and corticosteroids, not completely effective and limited by possible side effects and impairment of quality of life. Although immunological mechanisms of EoE are still less clear than other allergic diseases, biologic trials indicate some promising perspectives for EoE management. The purpose of this review is to present the current evidence of biologic drugs as options for EoE treatment.
Biblioteca responsable:
BR2717.9
Texto completo
Documentos relacionados